In clinical trials of once-daily or BID GLP-1 receptor agonists (liraglutide, lixisenatide, or exenatide BID), mean changes in body weight were 2.1 to 2.9 kg for monotherapy and +0.3 to 3.6 kg in combination with oral antihyperglycemic therapies (13,14,18)
531-P: Metabolomics Identifies Novel Plasma Metabolomic Signatures Associated with Diabetic Neuropathy in a Cohort with Screen-Tested Type 2 Diabetes: ADDITION-Denmark
Lactoferrin has several antibacterial properties and antiviral properties, and Im sure were going to get into more details, but the lactoferrin can be lost during the manufacturing process of creating that whey protein
As GLP-1 medications work on the brain and body to reduce appetite and promote weight loss, and cannabis can also affect appetite and metabolism, it is important to understand the potential implications of combining these substances
This solidifies their role as a foundational therapeutic option, not just a short-term intervention
A friend recommended I go talk to Gloria
